Craig Boerner

Kidney disease gene also has a protective mutation

African Americans have long been known to be at increased risk of kidney disease due to a dangerous genetic mutation that creates a hole in the kidney cells, but Vanderbilt researchers have now discovered a protective genetic mutation that covers the hole to eliminate the risk.

Effective medications for opioid use disorder rarely used

Vanderbilt research shows that most individuals diagnosed with opioid use disorder are not on recommended medications and even fewer remain in care.

World-first clinical trial to help millions with penicillin allergies

Many low-risk patients with a penicillin allergy were able to have their penicillin allergy label removed through a simple procedure known as “direct oral challenge” as part of a world-first multicenter randomized control trial known as the Penicillin Allergy Clinical Decision Rule (PALACE) study.

Musical rhythms shown to improve language processing in children with Developmental Language Disorder

Musical rhythms can help children with speech and language processing difficulties in finding their voice by improving their capacity to repeat sentences they just heard, according to a study led by a Western Sydney University researcher and co-authored by Vanderbilt University Medical Center.

Rett syndrome drug studied at Vanderbilt approved for patients

The first drug to treat the symptoms of Rett syndrome was recently approved, following a Nature Medicine study publishing results from the pivotal phase 3 LAVENDER study led by investigators from Vanderbilt University Medical Center to evaluate efficacy and safety of trofinetide.

Study finds Mark Cuban’s Cost Plus Drug Company could save taxpayers millions on Medicare generic oncology drugs

Vanderbilt research finds that the U.S. government could save taxpayers between $228 million-$2.15 billion a year if insurers who operate its Medicare Part D plans purchased seven generic oncology drugs at the same prices obtained by the Mark Cuban Cost Plus Drug Company.

1 2 3 4 18